CVS Health Corp


  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Doctors' group joins fight against high drug prices Tuesday, 3 Feb 2015 | 3:34 PM ET
    An undated handout photo provided by Gilead Sciences shows the hepatitis-C medication Sovaldi.

    A leading group of physicians is warning that high prices of specialty drugs is creating barriers to care for patients.

  • Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...

  • Cramer Remix: I've never seen anything like this Tuesday, 27 Jan 2015 | 7:13 PM ET
    Jim Cramer on Mad Money.

    In more than 30 years around Wall Street, “Mad Money” host Jim Cramer has seen a lot, but not this.

  • Cramer: Super Bowl stock face-off—Seahawks or NE? Tuesday, 27 Jan 2015 | 6:43 PM ET

    Seattle or New England? Jim Cramer goes off the charts with 4 companies.

  • Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...

  • Early movers: UNH, AAPL, NSP, NFLX, AMD & more Wednesday, 21 Jan 2015 | 8:05 AM ET

    Some of the names on the move ahead of the open.

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...

  • Your first trade for Wednesday Tuesday, 13 Jan 2015 | 6:14 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Jan 8- Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the...

  • Jan 8- AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. U.S. health regulators approved Viekira Pak, AbbVie's all-oral treatment for hepatitis C in December. AbbVie's newly approved regimen is also cheaper than Gilead's...

  • Cramer Remix: This stock can go a lot higher Wednesday, 7 Jan 2015 | 7:19 PM ET

    "Mad Money" host Jim Cramer actually suggests buying it into the next oil-induced selloff.

  • Flu boosts drug store sales, but others take a hit Wednesday, 7 Jan 2015 | 10:24 AM ET
    A woman receiving a flu vaccination in San Pablo, Calif.

    This year’s flu season is shaping up to be as bad as expected. That's good news for drug stores, but insurers and others could suffer.

  • Cramer Remix: Buy into this weakness Tuesday, 6 Jan 2015 | 7:03 PM ET
    Jim Cramer on Mad Money.

    The recent selloffs have been ugly, but "Mad Money" host Jim Cramer thinks you can buy these stocks into the red arrows.

  • Lightning Round: Don't fool around with this one Tuesday, 6 Jan 2015 | 6:51 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer's 10 lessons learned from 2014 Monday, 5 Jan 2015 | 6:10 PM ET
    Traders on the floor of the New York Stock Exchange.

    On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.

  • The euro fell to a near nine-year low against the dollar of $1.18605 on the EBS platform, tumbling on political uncertainty in Greece and fears of a possible Greek exit from the euro zone. The Greece question was front and center for Paul Nolte, portfolio manager at Kingsview Asset Management. "What you've done is thrown that entire area up for grabs, it will be very...

  • Jan 5- CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception. The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows...